search
Back to results

Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome

Primary Purpose

Metabolic Syndrome

Status
Withdrawn
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
fecal microbiota transplantation from healthy lean donors
Sponsored by
Catholic University of the Sacred Heart
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome

Eligibility Criteria

30 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Both males and females between 30 and 60 years old
  • BMI>30 and >35 kg/m2
  • Diagnosis of Metabolic Syndrome according to National Cholesterol Education Program's Adult Treatment Panel III criteria
  • No ongoing therapy for diabetes, hyperlipidemia or arterial hypertension
  • Signature of written informed consent

Exclusion Criteria:

  • recent (3 months) use of probiotic, antibiotics or other drugs
  • Increase in triglycerides levels, (≥ 300 mg/dl), LDL levels (≥ 190 mg/dl, or modification of body weight (±5%) during the last 3 months
  • Relevant cardiovascular diseases or kidney diseases
  • Relevant gastrointestinal diseases (such as inflammatory bowel disease or celiac disease)
  • Former gastrointestinal surgery

Sites / Locations

  • Catholic University of Sacred Heart - "A. Gemelli" University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control group

Fecal microbiota transplantation

Arm Description

Control group

Fecal microbiota transplantation from healthy lean donors

Outcomes

Primary Outcome Measures

difference in euglycemic clamp value at baseline and after the treatment

Secondary Outcome Measures

Disappearance of metabolic syndrome
Modification in fasting blood glucose
Modification in serum triglycerides
Modification in serum High Density Lipoprotein cholesterol
Modification in blood pressure
Modification in abdominal circumference
Modification in serum Tumor Necrosis Factor-alpha
Modification in serum C-Reactive Protein
Modification in serum interleukin-6
Modification in flow-mediated dilatation (FMD) of the brachial artery

Full Information

First Posted
November 7, 2013
Last Updated
July 13, 2020
Sponsor
Catholic University of the Sacred Heart
search

1. Study Identification

Unique Protocol Identification Number
NCT02050607
Brief Title
Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome
Official Title
Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Withdrawn
Study Start Date
January 2014 (undefined)
Primary Completion Date
July 2020 (Actual)
Study Completion Date
July 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Catholic University of the Sacred Heart

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Obesity is associated with changes in the composition and metabolic function of the gut microbiota. Fecal microbiota transplantation (FMT), also known as "fecal bacteriotherapy" or "fecal infusion", refers to the process of injecting a liquid suspension of stool from a healthy donor into the gastrointestinal (GI) tract of a patient to cure a specific disease. However, since the recently established concept of human gut microbiome and its significant role in health and disease has caught on in the medical scientific world, this procedure has gained a great pathophysiological strength, meaning not only the simple infusion of stools, but the transplantation of a healthy gut microbiota in a patient with a disrupted one. In a recent dutch experience, FMT from lean donors was able to increase the insulin sensitivity in patients with metabolic syndrome. Our primary aim is to evaluate if FMT from lean healthy donors, in association to lifestyle changes, is able to reduce insulin-resistance more than lifestyle changes alone in patients with metabolic syndrome. All the patients with metabolic syndrome will receive lifestyle counselling (1400 kilocalories diet and physical activity encouragement), than will be randomized to FMT from healthy lean donors by upper endoscopy (group A) or no treatment (group B)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
Control group
Arm Title
Fecal microbiota transplantation
Arm Type
Experimental
Arm Description
Fecal microbiota transplantation from healthy lean donors
Intervention Type
Other
Intervention Name(s)
fecal microbiota transplantation from healthy lean donors
Intervention Description
fecal microbiota transplantation from healthy lean donors
Primary Outcome Measure Information:
Title
difference in euglycemic clamp value at baseline and after the treatment
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Disappearance of metabolic syndrome
Time Frame
6 months
Title
Modification in fasting blood glucose
Time Frame
6 months
Title
Modification in serum triglycerides
Time Frame
6 months
Title
Modification in serum High Density Lipoprotein cholesterol
Time Frame
6 months
Title
Modification in blood pressure
Time Frame
6 months
Title
Modification in abdominal circumference
Time Frame
6 months
Title
Modification in serum Tumor Necrosis Factor-alpha
Time Frame
6 months
Title
Modification in serum C-Reactive Protein
Time Frame
6 months
Title
Modification in serum interleukin-6
Time Frame
6 months
Title
Modification in flow-mediated dilatation (FMD) of the brachial artery
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Both males and females between 30 and 60 years old BMI>30 and >35 kg/m2 Diagnosis of Metabolic Syndrome according to National Cholesterol Education Program's Adult Treatment Panel III criteria No ongoing therapy for diabetes, hyperlipidemia or arterial hypertension Signature of written informed consent Exclusion Criteria: recent (3 months) use of probiotic, antibiotics or other drugs Increase in triglycerides levels, (≥ 300 mg/dl), LDL levels (≥ 190 mg/dl, or modification of body weight (±5%) during the last 3 months Relevant cardiovascular diseases or kidney diseases Relevant gastrointestinal diseases (such as inflammatory bowel disease or celiac disease) Former gastrointestinal surgery
Facility Information:
Facility Name
Catholic University of Sacred Heart - "A. Gemelli" University Hospital
City
Rome
ZIP/Postal Code
00168
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome

We'll reach out to this number within 24 hrs